{‘She lacks no experience’: this US medical community prepares for Høeg's role at the FDA.

As the United States continues making sweeping changes to its vaccination guidelines, one figure has surfaced in a surprising turn: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by questioning coronavirus vaccinations in the global health crisis and has concentrated on potential deaths after COVID-19 vaccination in her short position at the US Food and Drug Administration (FDA).

Scheduled Shifts to Childhood Vaccine Program

Health officials planned to announce radical changes to the childhood vaccine schedule earlier this month, synchronizing the US with the Danish national calendar, sources say – a major change that would place the US out of alignment with a large portion of the world with insufficient data for benefit. This reveal has been delayed until the coming year.

Instead of the director of the vaccine center, Tracy Beth Høeg is set to speak at the gathering. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the center this year.

A Shift at the FDA

This interim role could signify a strengthened alliance between the pharmaceutical and biologics branches as Høeg and Prasad solidify control at the agency – and it signals a increased emphasis upon rolling back already-approved vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing specific childhood shot schedules in the US in order to be more similar to Denmark's approach, a country with universal health coverage and a number of inhabitants roughly the size of Wisconsin’s.

In her initial comments, she has kept her attention on immunizations – typically the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Questions Over Expertise

Høeg has little discernible track record in medication creation, approval processes or leadership, which has been customary for past directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the FDA chief and the vaccine center since March.

“She appears not to have any of the qualifications” for overseeing the CDER, said a neurologist and psychiatrist. “She has not conducted a clinical trial. She lacks experience in managing a sizeable institution. She is not an expert in drug approvals.”

Previous directors of the center would “grasp laws and regulations and the research of drug development”, noted Janet Woodcock. “Frankly, she has not acquired the kind of background that former directors who led CBER have had.”

This division has an immense workload at the FDA, the former commissioner emphasized.

“The public just zeroes in on the novel medication approvals, but the off-patent medication office authorizes numerous generic drugs. There’s a biologic copycat branch, OTC medication office and other areas, and every single one must be managed,” Dr. Woodcock explained. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

There is also, a major administrative component to the job, which supervises more than 5,000 staff members. “It is a enormous leadership role, if you perform it correctly,” the former official said.

Response and Contentious Programs

In response to concerns about Dr. Høeg's fitness for the role and whether this selection indicates more teamwork among FDA leaders on immunizations, a representative responded that the “inquiries are based on flawed premises”.

“This background aligns with the responsibilities of her role,” the spokesperson said, citing the period Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Høeg takes over the agency head's new expedited review system, a disputed one-day therapy clearance system that apparently troubled her predecessors. “How are these drugs being picked for this fast-track system? Who makes the calls?” Dr. Howard asked. “There is a lot of secrecy happening at the regulatory body right now.”

In general, he remarked, “the agency seems to be moving towards less stringent oversight of all drugs, except for vaccines.”

Documented History on Immunizations

Concerning vaccines, Dr. Høeg has a more established, if problematic, history, some experts observe. She authored a analysis using unconfirmed volunteer-provided data to estimate the incidence of heart inflammation following COVID-19 immunization. She consulted for the Florida top health official Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccinations are pose a greater threat than they are.

Among her “policy goals” for the new government included altering regulations for recently developed shots and ending “optional” immunizations, she said after the election on a online show. At the agency, Dr. Høeg has reportedly proposed excluding young men from getting COVID-19 vaccinations.

“She is an complete ideologue who commences with her preconceived notions and tailors the evidence to accommodate the science in a extremely deceptive, fraudulent fashion,” Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg aligned with other skeptics, {like|